Zepbound and Mounjaro both contain tirzepatide. That shared ingredient does not make the names interchangeable when discussing approved uses, insurance, or the instructions for a particular presentation.
The comparison below uses the current prescribing information checked on September 23, 2026. It is intended to help you ask a precise question of your clinician, not to choose or switch treatment yourself.
Ask which product is proposed and what condition it is intended to treat. An ingredient match is only the beginning.
Zepbound’s labeled purposes
Zepbound’s label includes chronic weight-management use for qualifying adults with obesity or overweight and a weight-related condition, alongside diet and activity measures. It also includes treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Those indications have clinical conditions and limitations; they are not an invitation to self-diagnose eligibility. Ask your clinician which indication, if any, fits your situation. The LillyDirect review discusses an access route after keeping that clinical question separate.
Mounjaro’s current label is different
Mounjaro is indicated alongside diet and exercise to improve blood-sugar control in adults and children aged 10 years and older with type 2 diabetes. Its August 2026 label also includes reducing major adverse cardiovascular-event risk in adults with type 2 diabetes who are at high risk for these events.
That is why older summaries describing Mounjaro only in terms of adult blood-sugar control can be incomplete. This site focuses on adult education; pediatric treatment requires its own specialist discussion. Do not assume a weight-management advertisement accurately summarizes the current Mounjaro label.
What to bring to an insurance or provider discussion
Use the full product name, proposed purpose, and presentation when requesting a coverage or cost estimate. Ask whether prior authorization is required and who handles it. A service offering support with paperwork cannot guarantee payment by your insurer.
Compounded tirzepatide is a separate category and is not an FDA-approved generic version of either product. Read the compounding guide and cost fieldnote before comparing these options on price alone. The first-appointment guide helps put the questions in a useful order.
Sources: NIDDK: Prescription medicines for overweight and obesity · Mochi Health: Public care and pricing FAQs · FDA: Concerns with unapproved GLP-1 drugs
The source shelf
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- NIDDK: Prescription medicines for overweight and obesity
Chronic weight-management decisions and ongoing lifestyle care.
- Mochi Health: Public care and pricing FAQs
Membership, medication and insurance pathways must be distinguished.
- FDA: Concerns with unapproved GLP-1 drugs
Compounding, fraudulent labels, dosing errors and the limits of adverse-event reports. Checked September 23, 2026.
